FORESEEA GREAT FUTURE?



© CIDETEC 2020

complex











nanomedicine

© CIDETEC 2023



CIDETEC Nanomedicine is an applied research centre specialising in the development of innovative technologies & biomaterials.





We provide solutions



Drug delivery technologies for the pharmaceutical sector



Encapsulation technologies for the cosmetic sector




Biomaterials for medical devices for use in traumatology and ophthalmology



We are technology and R&D service providers in the innovation value chain

Specialist in the development of advanced materials for the biomedical and cosmetic sector





HEU active projects in 2023









HORIZON-HLTH-2021-TOOL-06-02 Next generation advanced therapies to treat highly prevalent and high burden diseases with unmet medical needs (RIA)

9 projects funded under this topic / 31 proposals submitted

Cost effective combined advanced therapy to treat knee osteoarthritis

SINPAIN project aims at developing siRNA advanced therapies pipeline products for the treatment of early (grade 0-1) and later stages (grade 3-4) of knee osteoarthritis (OA).

Duration 54 months Budget 5.3 Mill € **Project partners** 12 Funding HEU



VISION

Our vision is to improve the quality of life for those affected by osteoarthritis (OA) and reduce the substantial costs associated with the disease.

MISSION

SINPAIN aims to develop a pipeline of safe, efficient, and cost-effective advanced siRNA therapies that will revolutionise knee OA treatment.



OA ranks among the most common joint disorders worldwide.



Long considered a 'wear and tear' condition of the elderly, it is now known that OA is a highly complex disease of the entire joint.


OA affects 7 % of the global population, of which 40 million live in Europe.



Symptoms


OA is a degenerative disease that can affect one or several joints, but most commonly the diarthrodial joints, namely the hip, hand, and knee.

Major symptoms include:



Progression of OA

Kellgren-Lawrence Classification of Knee Osteoarthritis








Grade 3 Moderate (large area of cartilage damage, appearance of bone spurs, osteophytes) Grade 4 Severe (bone-on-bone contact and growth of osteophytes)




Current OA Treatment Options

Current treatment options are often costly and inefficient. In addition to a difficult diagnosis, all of these measures can only slow the progression of degenerative arthritis. Plus, taking medications often shows only limited success, and at the same time can lead to gastric complications and other potential adverse side effects.

The SINPAIN Approach






As a delivery system, SINPAIN will use a material with dynamic properties to:

- 1. Mimic the rheological properties of natural synovial fluid to hydrate and protect cartilage
- 2. Restore the healthy conditions of the knee through a locally administered gene therapy
- 3. Incorporate pro-regenerative cues to promote healing of damaged cartilage.

SINPAIN The SINPAIN Research Pipeline









Featured Projects

FORCE REPAIR



HORIZON-CL4-2022-RESILIENCE-01-13 Smart and multifunctional biomaterials for health innovations (RIA)

8 projects funded under this topic / 100 proposals submitted

Smart, multifunctional, and cost-effective 3D-printed wound dressing to help control bacterial infection and inflammation in chronic wounds.

The innovative FORCE REPAIR scaffold will stimulate healing, facilitate wound care management, and thus help reduce associated healthcare costs by decreasing significantly the daily frequency of nurse visits.

Duration
4 years
Budget
5.1 Mill €
Project partners
14

Funding

HEU



MISSION & VISION

VISION

Our vision is to improve chronic wound treatment, reduce healthcare costs, and improve patients' overall quality of life

MISSION

Our mission is to set out to advance chronic wound management by developing a smart, multifunctional, and cost-effective 3D-printed wound dressing to help control bacterial infection and inflammation


OBJECTIVES







CONCEPT





FORCE REPAIR CONSORTIUM

PROJECT PARTNERS	Country	
FUNDACIÓN CIDETEC (CID)	ES	
UNIVERSITA DEGLI STUDI DEL PIEMONTE ORIENTALE AMEDEO AVOGADRO (UPO)	IT	
HISTOCELL (HCELL)	ES	
EURICE EUROPEAN RESEARCH AND PROJECT OFFICE GMBH (EURICE)	DE	
ASPHALION S.L. (ASPH)	ES	EURICE betthera
AKRIBES BIOMEDICAL GMBH (AKR)	AT	PROJECT OFFICE CAMEN
FUNDACIÓN IDONIAL (IDO)	ES	O Akribes
BETTHERA S.R.O (BETT)	CZ	
FUNDACIÓN VICOMTECH (VICOM)	ES	
EUROPEAN WOUND MANAGEMENT ASSOCIATION (EWMA)	DK	
UNIVERSITA DEGLI STUDI DI PAVIA (UNIPV)	IT	histocell di pavia
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)	FR	vicomtech ASPHALION
JOANNEUM RESEARCH FORSCHUNGSGESELLSCHAFT MBH (JOAN)	AT	cidetec>
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)	FR	



What to take into account?

Program Understanding	Call Analysis	Project Idea	Writing	Project Execution
Partnerships	Understand what	Alignment with	Clear idea	Good
is asked Work Program Type of action (TRLs) Does my idea fit? Core expertise required Do you know already someone that may cover your needs?	topic & EU Policies	Keep exploitation in mind.	communication & coordination	
	Innovation vs market requirements	Define partners responsibilities	Use risk analysis for complicated situations	
	Core expertise	Cover Scopes & Expected Outcomes Unique Selling Point. Why you?	Background & Foreground	Continuous communication
	already someone that may cover		Risk Analysis & Mitigation strategy	with your officer 20



What have we learnt?

Do not limit yourself to Cluster 1 – The topic must fit

Regulation & Market Access Strategy.

Innovation + Translation – the key to success.

A credible exploitation strategyFundraising strategies for next steps

Define well your IP

Background, shared foreground (exploitation obligations)
 License and co-ownership agreements

Risk Analysis & Mitigation Strategy.



Andrea Haiek ahaiek@cidetec.es



a greater future today

© CIDETEC 2023